Metabolic disease companies develop therapies, diagnostics and research technologies for disorders affecting how the body processes and stores energy. Their work spans diabetes, obesity, fatty liver disease and inherited metabolic conditions.
This category includes companies working on:
Browse 53 UK metabolic disease companies below.
Brain-inspired AI platform for multi-target drug discovery
Symbiotic.blue is a pre-seed biotech company developing an AI-driven drug discovery platform that combines generative AI with neuroscience-inspired computational methods. The platform aims to design molecules capable of acting on multiple biological targets simultaneously, with an initial focus on obesity. The company…
Oral and injectable peptide therapies for obesity and cardiometabolic disease
Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable treatments for obesity and cardiometabolic disorders. Its pipeline centres on rationally engineered peptide candidates acting on GLP-1 and amylin receptors, advanced through a proprietary oral absorption technology…
UK affiliate of global family-owned biopharmaceutical company
Boehringer Ingelheim is a global family-owned biopharmaceutical company founded in 1885. Its Bracknell headquarters houses functions spanning research and development, regulatory affairs, pharmacovigilance, medical affairs, and commercial operations across its human pharma and animal health divisions. It operates…
Microbiome modulator ingredients for metabolic health and disease prevention
OptiBiotix Health is a biotechnology company developing and licensing microbiome modulator products for use in food ingredients, dietary supplements, and nutraceuticals. Its portfolio includes patented prebiotic and probiotic formulations targeting weight management, cholesterol reduction, cardiovascular health, and…
UK commercial base for a rare metabolic disease biotech
Amicus Therapeutics UK is the British subsidiary of Amicus Therapeutics, a US-listed biotechnology company focused on rare metabolic diseases. The company develops enzyme replacement therapies and gene therapies targeting lysosomal storage disorders, with approved medicines for Pompe disease and Fabry disease. The UK…
Oral iron deficiency therapy for adults across multiple indications
Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on iron deficiency. Its lead product, Accrufer/Feraccru (ferric maltol), is an oral iron therapy approved for adults with iron deficiency with or without anaemia. The product is commercialised in the US with Viatris and licensed to…
AAV gene therapy for Bardet-Biedl syndrome and genetic obesity
Axovia Therapeutics is a biotechnology company developing adeno-associated viral gene therapies for inherited ciliopathies and genetic obesity. Its lead candidate delivers a functional BBS1 gene into retinal cells to investigate treatment of vision loss associated with Bardet-Biedl syndrome. A first-in-human, early…
Mitochondrial sulfide-donor therapeutics for obesity and myopathies
MitoRx Therapeutics is a company developing first-in-class small molecule therapeutics that target mitochondrial sulfide signalling, a mechanism implicated in metabolic dysfunction and muscle disease. Its lead programme is an injectable mitochondria-targeted sulfide donor designed to achieve fat loss without lean mass…
Takeda's UK clinical development and drug discovery operations
Takeda UK encompasses the British operations of Takeda Pharmaceutical Company, one of the world's largest biopharmaceutical companies. The London-based Takeda Development Centre Europe leads clinical development, regulatory affairs, and medical affairs across oncology, neuroscience, gastrointestinal disease, rare…
Preclinical CRO for receptor pharmacology and occupancy studies
Gifford Bioscience is a contract research organisation providing receptor pharmacology and occupancy services for preclinical and discovery stage drug development. The company conducts radioligand binding assays, functional GPCR assays, receptor occupancy studies, autoradiography, and surface plasmon resonance using…
Oral NLRP3 inhibitors for cardiovascular and neurologic inflammation
Rezera, formerly NodThera, is a clinical-stage biotechnology company developing small molecule inhibitors of NLRP3, an inflammasome implicated in chronic inflammatory and neurodegenerative disease. Its lead asset, ruvonoflast, is a brain-penetrant oral inhibitor that has completed Phase II trials and is advancing…
Specialist preclinical CRO for ophthalmic retinal disease drug development
MediNect Ophtho is a contract research organisation providing specialist preclinical services for ophthalmic drug development, with an exclusive focus on retinal disease. Operating from Belfast, the company offers in vivo and ex vivo retinal disease models, proof-of-concept studies, DMPK and ADME studies, and…
Single-pill fixed-dose combinations for cardiometabolic disease
George Medicines is a late-stage biopharmaceutical company developing innovative single-pill, fixed-dose combination therapies for cardiometabolic diseases. Rather than pursuing early drug discovery, the company reformulates established best-in-class small molecules into novel proprietary low-dose combinations…
Oral muscle-sparing small molecule therapies for obesity
Hawkhill Therapeutics is a pre-clinical biotechnology company developing oral, muscle-sparing therapeutics for obesity and metabolic health. Its programme targets a clinically validated mechanism to achieve fat-selective weight loss while preserving muscle mass, addressing a recognised limitation of current GLP-1…
Blood-based liquid biopsy for endothelial glycocalyx and microvascular health
Dimension Biotechnologies is a biotech developing a rapid, blood-based diagnostic for microvascular health based on analysis of the endothelial glycocalyx, the molecular layer lining blood vessel walls whose biochemical integrity is disrupted early in cardiovascular disease, kidney disease, diabetes, and sepsis. The…
Synthetic glucose-binding molecules for continuous glucose monitoring
Carbometrics Limited is a supramolecular chemistry biotech developing synthetic Glucose Binding Molecules (GBMs) for use in continuous glucose monitoring sensors and other diagnostic applications. The GBM platform uses a precisely engineered small-molecule scaffold to selectively bind glucose with high affinity and…
GC-IMS analytical instruments for clinical, food and environmental testing
Imspex Diagnostics is a Welsh analytical instruments company developing and distributing Gas Chromatography-Ion Mobility Spectrometry platforms for clinical diagnostics, food safety and environmental analysis. Its GC-IMS technology detects target compounds and clinical biomarkers at parts-per-billion sensitivity,…
Genomics platform developing RNA therapies for chronic liver disease
Ochre Bio is a biotechnology company developing RNA therapeutics for chronic liver disease using a platform built on large-scale human liver datasets. The platform integrates gene perturbation atlases, single-cell genomics from perfused donor livers, and machine learning to identify and validate disease-modifying drug…
Circadian hormone therapeutics for rare endocrine conditions
Neurocrine UK is the European operations of Neurocrine Biosciences, a Cardiff-headquartered specialty pharmaceutical company developing and commercialising hormone therapeutics for rare and chronic endocrine conditions. The company's scientific approach centres on circadian-based formulation technology, designed to…
DNA-based gene therapy platform for intercellular therapeutic gene delivery
Bitrobius Genetics is a UK biotech developing a novel DNA-based gene therapy platform technology designed to deliver functional copies of mutated genes to cells within a target tissue or organ. Its platform is based on the principle of DNA replication and intercellular transmission, aiming to achieve broad tissue…